Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW597599 plus paroxetine versus paroxetine alone versus placebo in social anxiety disorder
2004-001894-24Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing GW597599 + paroxetine, paroxetine monotherapy and placebo (3 arms). Primary endpoint: Change from baseline in Liebowitz Social Anxiety Scale total score at Week 12. Started Sep 2004; status: completed.
02
Drugs
vestipitantparoxetine
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on 2004-001894-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001894-24.